Defibrillators in nonischemic cardiomyopathy treatment evaluation

PACE - Pacing and Clinical Electrophysiology

Volumn 23, Issue 3, 2000, Pages 338-343

  Kadish, Alan ^a,e   Quigg, Rebecca ^a   Schaechter, Andi ^a   Anderson, Kelley P ^b   Estes, Mark ^c   Levine, Joseph ^d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d ST FRANCIS HOSPITAL   (United States)

^e NORTHWESTERN MEMORIAL HOSPITAL   (United States)

Author keywords

ICD; Nonischemic cardiomyopathy; Nonsustained ventricular tachycardia

Indexed keywords

ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTICLE; CARDIOMYOPATHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEFIBRILLATOR; HEART VENTRICLE TACHYCARDIA; HUMAN; IMPLANTATION; MORTALITY; MULTICENTER STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

EID: 0034019056     PISSN: 01478389     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2000.tb06759.x     Document Type: Article

References (31)

1. 1. Luu M, Stevenson W, Stevenson L. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation 1989; 80:1675-1680.
2. 2. Moss A, Hall W, Cannon D. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996; 335:1933-1940.
3. 3. Levine J, Waller T, Hoch D, et al. Implantable cardioverter defibrillator: Use in high asymptomatic individuals. Am Heart J 1996; 131:59-65.
4. 4. Cohn J, Archibald D, Ziesche S. Effect of vasodilator therapy on mortality in chronic congestive heart failure: Results of a Veterans Administration cooperative study. N Engl J Med 1986; 314:1547-1552.
5. 5. Cohn J, Johnson G, Ziesche S. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic heart failure (V-HeFt II - Veterans Health Failure Trial II). N Engl J Med 1991; 325:303-310.
6. 6. Swedberg K, Kjekshus J. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandanavian Enalapril Survival Study (CONSENSUS). Am J Cardiol 1988; 62:60A-66A.
7. 7. Fonarow G, Chelimsky-Falllick C, Warner-Stevenson J. Effect of direct vasodilation with hydralizine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: The Hy-C Trial. J Am Coll Cardiol 1992; 19:842-850.
8. 8. Pfeffer M, Braunwald E, Moyee L. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the survival and ventricular enlargement trial. N Engl J Med 1992; 327:699-677.
9. 9. Waagstein F, Bristow M, Swedberg K. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993; 32:1441-1446.
10. 10. Packer M, Bristow M, Cohn J. The effect of Carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334:1349-1397.
11. 11. Heidenreich P, Lee T, Massie B. Effect of beta-blockade on mortality in patients with heart failure: A meta-analysis of randomized clinical trials. J Am Coll Cardiol 1997; 30:27-34.
12. 12. Packer M, Gheorghiade M, Young J. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. New Engl J Med 1993; 329:1-7.
13. 13. The Digitalis Investigation Group: The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336:525-533.
14. 14. Waldo A, Camm A, DeRuyter H. Effect of d-sotalol on mortality in patients with left ventricular dysfunction and recent and remote myocardial infarction. Lancet 1996; 348:7-12.
15. 15. (CAST) Investigators Preliminary report: Effect of endainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321:406-410.
16. 16. Singh S, Fletcher R, Fisher S. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995: 333:77-82.
17. 17. Doval H, Nul D, Grancelli H. Randomized trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994; 1:493-498.
18. 18. Doval H, Nul D, Grancelli H. Nonsustained ventricular tachycardia in severe heart failure. Circulation 1996; 94:3198-3203.
19. 19. Connolly S, Cairns J, Gent M, et al. Effects of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: Meta-analysis of individual data from 6,500 patients in randomized trials. Lancet 1997; 350:1417-1424.
20. 20. Pogwizd S, McKenzie J, Cain M. Mechanisms underlying spontaneous and induced ventricular arrhythmias in patients with idiopathic dilated cardiomyopathy. Circulation 1998; 98:2404-2414.
21. 21. Singh S, Fisher S, Carsion P, et al. Prevalence and significance of nonsustained ventricular tachycardia in patients with premature ventricular contractions and heart failure treated with vasodilator therapy. J Am Coll Cardiol 1998; 32:942-947.
22. 22. Grimm W, Hoffmann J, Menz V, et al. Programmed ventricular stimulation for arrhythmia risk prediction in patients with idiopathic dilated cardiomyopathy and nonsustained ventricular tachycardia. J Am Coll Cardiol 1998; 32:739-745.
23. 23. Rector T, Kubo S, Cohn J. Patients self-assessment of their congestive heart failure: Content, reliability and validity of a new measure, the Minnesota Living with Heart Failure Questionnaire. Heart Failure 1987; 3:198-209.
24. 24. Rector T, Cohn J. Assessment of patient outcome with the Minnesota Living with Heart Failure Questionnaire: Reliability and validity during a randomized, double-blind, placebo-controlled trial of Pimobenden. Am Heart J 1992; 124:1017-1025.
25. 25. Guyatt G, Nogradi S, Halcrow S, et al. Development and testing of a new measure of health status for clinical trials in heart failure. J Gen Intern Med 1989; 4:101-107.
26. 26. Ware J, Sherbourne C. A 12-Item Short-form Health Survey: Construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34:220-233.
27. 27. Epstein A, Carison M, Fogoros R, et al. Classification of death in antiarrhythmia trials. J Am Coll Cardiol 1996; 26:433-442.
28. 28. Whitehead J, Stratton I. Group sequential trials with triangular continuation regions. Biometrics 1983; 39:227-236.
29. 29. Kim K, DeMets D. Design and analysis of group sequential tests based on the type I error spending function. Biometrika 1987; 74:149-154.
30. 30. Kim K, Tsiatis A. Study duration for clinical trials with survival response and early stopping rule. Biometrics 1990; 46:81-92.
31. 31. Kim K, DeMets D. Sample size determination for group sequential clinical trials with immediate response. Stat Med 1992; 11:1391-1399.